Vistagen Therapeutics Overview
- Year Founded
-
1998
- Status
-
Public
- Employees
-
41
- Stock Symbol
-
VTGN
- Investments
-
3
- Share Price
-
$0.18
- (As of Friday Closing)
Vistagen Therapeutics General Information
Description
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Contact Information
Website
www.vistagen.comCorporate Office
- 343 Allerton Avenue
- South San Francisco, CA 94080
- United States
Corporate Office
- 343 Allerton Avenue
- South San Francisco, CA 94080
- United States
Vistagen Therapeutics Stock Performance
As of 13-Nov-2026, Vistagen Therapeutics’s stock price is $0.18. Its current market cap is $8.01M with 44.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.18 | $0.18 | $0.16 - $5.14 | $8.01M | 44.4M | 10.2M | -$1.36 |
Vistagen Therapeutics Financials Summary
As of 30-Sep-2026, Vistagen Therapeutics has a trailing 12-month revenue of $2.38M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | (17,288) | (37,700) | (14,692) | 18,389 |
| Revenue | 2,382 | 1,269 | 486 | 1,064 |
| EBITDA | (59,781) | (71,386) | (55,333) | (32,141) |
| Net Income | (58,943) | (69,685) | (51,418) | (29,362) |
| Total Assets | 23,421 | 48,564 | 84,341 | 123,653 |
| Total Debt | 610 | 1,044 | 1,509 | 2,120 |
Vistagen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Vistagen Therapeutics Comparisons
Industry
Financing
Details
Vistagen Therapeutics Competitors (10)
One of Vistagen Therapeutics’s 10 competitors is Aptinyx, a Formerly VC-backed company based in Evanston, IL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aptinyx | Formerly VC-backed | Evanston, IL | ||||
| Relmada Therapeutics | Formerly VC-backed | Coral Gables, FL | ||||
| Intracellular Therapies | Formerly VC-backed | Bedminster, NJ | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA | ||||
| Axsome Therapeutics | Formerly VC-backed | New York, NY |
Vistagen Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Vistagen Therapeutics Patents
Vistagen Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025254394-A1 | Intranasal drug delivery system | Pending | 08-Apr-2024 | ||
| US-20250312544-A1 | Intranasal drug delivery system | Pending | 08-Apr-2024 | ||
| WO-2025217067-A1 | Intranasal drug delivery system | Pending | 08-Apr-2024 | ||
| AU-2025252713-A1 | Treatment of dysmenorrhea | Pending | 08-Apr-2024 | ||
| US-20250312356-A1 | Treatment of dysmenorrhea | Pending | 08-Apr-2024 | A61K31/568 |
Vistagen Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Vistagen Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Vistagen Therapeutics Acquisitions (3)
Vistagen Therapeutics’s most recent deal was a Merger/Acquisition with Pherin Pharmaceuticals for . The deal was made on 02-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Pherin Pharmaceuticals | 02-Feb-2023 | Merger/Acquisition | Drug Discovery | ||
| Excaliber Enterprises | 11-May-2011 | Merger/Acquisition | Distributors/Wholesale | ||
| Artemis Neuroscience | 19-Nov-2003 | Merger/Acquisition | Drug Discovery |
Vistagen Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.07 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Vistagen Therapeutics FAQs
-
When was Vistagen Therapeutics founded?
Vistagen Therapeutics was founded in 1998.
-
Where is Vistagen Therapeutics headquartered?
Vistagen Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Vistagen Therapeutics?
Vistagen Therapeutics has 41 total employees.
-
What industry is Vistagen Therapeutics in?
Vistagen Therapeutics’s primary industry is Drug Discovery.
-
Is Vistagen Therapeutics a private or public company?
Vistagen Therapeutics is a Public company.
-
What is Vistagen Therapeutics’s stock symbol?
The ticker symbol for Vistagen Therapeutics is VTGN.
-
What is the current stock price of Vistagen Therapeutics?
As of 13-Nov-2026 the stock price of Vistagen Therapeutics is $0.18.
-
What is the current market cap of Vistagen Therapeutics?
The current market capitalization of Vistagen Therapeutics is $8.01M.
-
What is Vistagen Therapeutics’s current revenue?
The trailing twelve month revenue for Vistagen Therapeutics is $2.38M.
-
Who are Vistagen Therapeutics’s competitors?
Aptinyx, Relmada Therapeutics, Intracellular Therapies, ACADIA Pharmaceuticals, and Axsome Therapeutics are some of the 10 competitors of Vistagen Therapeutics.
-
What is Vistagen Therapeutics’s annual earnings per share (EPS)?
Vistagen Therapeutics’s EPS for 12 months was -$1.36.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
